Lymphoma market turf war imminent, pending Bexxar approval.
Garber
Ken
K
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D003132:Commerce / Q000191:economics; D017277:Drug Approval; D004465:Economic Competition; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000191:economics* / Q000532:radiotherapy*; D040541:Marketing / Q000191:economics; D016499:Radioimmunotherapy / Q000191:economics*; D055502:Secondary Prevention; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; C422802:ibritumomab tiuxetan